Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001918592 | SCV002177793 | uncertain significance | Renal cell carcinoma | 2021-08-16 | criteria provided, single submitter | clinical testing | This sequence change replaces valine with isoleucine at codon 941 of the MET protein (p.Val941Ile). The valine residue is highly conserved and there is a small physicochemical difference between valine and isoleucine. This variant is not present in population databases (ExAC no frequency). This variant has not been reported in the literature in individuals affected with MET-related conditions. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Tolerated"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C0"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV002441018 | SCV002746665 | uncertain significance | Hereditary cancer-predisposing syndrome | 2022-03-11 | criteria provided, single submitter | clinical testing | The p.V941I variant (also known as c.2821G>A), located in coding exon 12 of the MET gene, results from a G to A substitution at nucleotide position 2821. The valine at codon 941 is replaced by isoleucine, an amino acid with highly similar properties. This amino acid position is conserved. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |